Ifosfamide in testicular cancer: The Indiana University experience

P. J. Loehrer, S. D. Williams, L. H. Einhorn

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The systemic treatment of patients with metastatic germ cell tumors has improved dramatically during the past 15 years. Nonetheless, a cohort of patients are candidates for salvage chemotherapy. Having ruled out the possibility of pseudoprogression (eg, false elevated serum markers, teratoma, bleomycin lung disease), salvage therapy is indicated. Numerous trials in Europe and at Indiana University have confirmed single-agent activity of ifosfamide in patients with refractory germ cell tumors. As a consequence, a trial evaluating VeIP (vinblastine, ifosfamide, cisplatin) and VIP (etoposide, ifosfamide, cisplatin) was undertaken in 57 patients previously not cured with cisplatin, vinblastine, and etoposide regimens. Twenty patients achieved disease-free status with chemotherapy alone (n = 12) or chemotherapy plus surgical resection of residual carcinoma or teratoma (n = 8). Fifteen of these 20 patients remained free of recurrent disease from 18 to 53 months, including seven patients in continuous remission for over 2 years. Ifosfamide combination chemotherapy has curative potential in this heavily pretreated population. Further work to determine the role of ifosfamide in initial therapy is under way.

Original languageEnglish (US)
Pages (from-to)96-101
Number of pages6
JournalSeminars in oncology
Volume16
Issue number1 SUPPL. 3
StatePublished - Jan 1 1989

Fingerprint

Ifosfamide
Testicular Neoplasms
Cisplatin
Vinblastine
Germ Cell and Embryonal Neoplasms
Teratoma
Etoposide
Drug Therapy
Salvage Therapy
Bleomycin
Combination Drug Therapy
Lung Diseases
Biomarkers
Carcinoma
Therapeutics
Population

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Ifosfamide in testicular cancer : The Indiana University experience. / Loehrer, P. J.; Williams, S. D.; Einhorn, L. H.

In: Seminars in oncology, Vol. 16, No. 1 SUPPL. 3, 01.01.1989, p. 96-101.

Research output: Contribution to journalArticle

@article{1acbee424e774c878c81dc79f122c253,
title = "Ifosfamide in testicular cancer: The Indiana University experience",
abstract = "The systemic treatment of patients with metastatic germ cell tumors has improved dramatically during the past 15 years. Nonetheless, a cohort of patients are candidates for salvage chemotherapy. Having ruled out the possibility of pseudoprogression (eg, false elevated serum markers, teratoma, bleomycin lung disease), salvage therapy is indicated. Numerous trials in Europe and at Indiana University have confirmed single-agent activity of ifosfamide in patients with refractory germ cell tumors. As a consequence, a trial evaluating VeIP (vinblastine, ifosfamide, cisplatin) and VIP (etoposide, ifosfamide, cisplatin) was undertaken in 57 patients previously not cured with cisplatin, vinblastine, and etoposide regimens. Twenty patients achieved disease-free status with chemotherapy alone (n = 12) or chemotherapy plus surgical resection of residual carcinoma or teratoma (n = 8). Fifteen of these 20 patients remained free of recurrent disease from 18 to 53 months, including seven patients in continuous remission for over 2 years. Ifosfamide combination chemotherapy has curative potential in this heavily pretreated population. Further work to determine the role of ifosfamide in initial therapy is under way.",
author = "Loehrer, {P. J.} and Williams, {S. D.} and Einhorn, {L. H.}",
year = "1989",
month = "1",
day = "1",
language = "English (US)",
volume = "16",
pages = "96--101",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "1 SUPPL. 3",

}

TY - JOUR

T1 - Ifosfamide in testicular cancer

T2 - The Indiana University experience

AU - Loehrer, P. J.

AU - Williams, S. D.

AU - Einhorn, L. H.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - The systemic treatment of patients with metastatic germ cell tumors has improved dramatically during the past 15 years. Nonetheless, a cohort of patients are candidates for salvage chemotherapy. Having ruled out the possibility of pseudoprogression (eg, false elevated serum markers, teratoma, bleomycin lung disease), salvage therapy is indicated. Numerous trials in Europe and at Indiana University have confirmed single-agent activity of ifosfamide in patients with refractory germ cell tumors. As a consequence, a trial evaluating VeIP (vinblastine, ifosfamide, cisplatin) and VIP (etoposide, ifosfamide, cisplatin) was undertaken in 57 patients previously not cured with cisplatin, vinblastine, and etoposide regimens. Twenty patients achieved disease-free status with chemotherapy alone (n = 12) or chemotherapy plus surgical resection of residual carcinoma or teratoma (n = 8). Fifteen of these 20 patients remained free of recurrent disease from 18 to 53 months, including seven patients in continuous remission for over 2 years. Ifosfamide combination chemotherapy has curative potential in this heavily pretreated population. Further work to determine the role of ifosfamide in initial therapy is under way.

AB - The systemic treatment of patients with metastatic germ cell tumors has improved dramatically during the past 15 years. Nonetheless, a cohort of patients are candidates for salvage chemotherapy. Having ruled out the possibility of pseudoprogression (eg, false elevated serum markers, teratoma, bleomycin lung disease), salvage therapy is indicated. Numerous trials in Europe and at Indiana University have confirmed single-agent activity of ifosfamide in patients with refractory germ cell tumors. As a consequence, a trial evaluating VeIP (vinblastine, ifosfamide, cisplatin) and VIP (etoposide, ifosfamide, cisplatin) was undertaken in 57 patients previously not cured with cisplatin, vinblastine, and etoposide regimens. Twenty patients achieved disease-free status with chemotherapy alone (n = 12) or chemotherapy plus surgical resection of residual carcinoma or teratoma (n = 8). Fifteen of these 20 patients remained free of recurrent disease from 18 to 53 months, including seven patients in continuous remission for over 2 years. Ifosfamide combination chemotherapy has curative potential in this heavily pretreated population. Further work to determine the role of ifosfamide in initial therapy is under way.

UR - http://www.scopus.com/inward/record.url?scp=0024564254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024564254&partnerID=8YFLogxK

M3 - Article

C2 - 2539649

AN - SCOPUS:0024564254

VL - 16

SP - 96

EP - 101

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 1 SUPPL. 3

ER -